{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T03:11:06Z","timestamp":1769742666484,"version":"3.49.0"},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Stem cell transplantation (SCT) has been an integral treatment modality for multiple myeloma (MM) for decades. However, as standard\u2010of\u2010care therapies have improved, the benefit of SCT has been repeatedly called into question. This retrospective study evaluated the association between SCT in the first line of therapy (LOT) and outcomes for patients with newly diagnosed multiple myeloma (NDMM) in the United States. We included patients from a de\u2010identified electronic health record\u2010derived database who initiated front\u2010line MM therapy between January 1, 2016, and January 31, 2022. Overall, 18.8% (1127 of 5996 patients) received SCT in the first LOT. Multivariable\u2010adjusted Cox proportional hazards models, in which SCT was modeled as time varying, revealed longer real\u2010world progression\u2010free survival (rwPFS; hazard ratio [HR] 0.49; 95% confidence interval [CI] 0.43\u20130.57) and real\u2010world overall survival (rwOS; HR 0.47; 95% CI 0.39\u20130.56) for patients who received SCT in the first LOT. The degree of rwPFS and rwOS benefit imparted by SCT was consistent across all subgroups examined, including patients aged \u226575 years, women, non\u2010Hispanic Black\/African American patients, those with renal impairment, and those with high\u2010risk cytogenetics. Findings from this analysis of real\u2010world patients with NDMM suggest that SCT remains an important standard of care in the era of novel therapies.<\/jats:p>","DOI":"10.1002\/jha2.739","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T08:40:21Z","timestamp":1691138421000},"page":"984-994","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real\u2010world multiple myeloma front\u2010line treatment and outcomes by transplant in the United States"],"prefix":"10.1002","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Pan","sequence":"additional","affiliation":[{"name":"Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Salinardi","sequence":"additional","affiliation":[{"name":"Sanofi Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan S.","family":"Rice","sequence":"additional","affiliation":[{"name":"Sanofi Cambridge Massachusetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"2","key":"e_1_2_13_2_1","article-title":"Multiple myeloma: EHA\u2010ESMO clinical practice guidelines for diagnosis, treatment and follow\u2010up","volume":"5","author":"Dimopoulos MA","year":"2021","journal-title":"Hemasphere"},{"key":"e_1_2_13_3_1","unstructured":"American Cancer Society Cancer Statistics Center.2022 estimates.2022. Available from:https:\/\/cancerstatisticscenter.cancer.org\/#!\/. Accessed 3 Apr 2022."},{"key":"e_1_2_13_4_1","unstructured":"National Institutes of Health Surveillance Epidemiology and End Results Program.Cancer stat facts: myeloma.2021. Available from:https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed 24 May 2022."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_13_6_1","unstructured":"National Comprehensive Cancer Network.Multiple myeloma version 5.2022. Available from:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed 24 May 2022."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0804-4"},{"key":"e_1_2_13_8_1","unstructured":"BirnbaumB NussbaumN Seidl\u2010RathkopfK AgrawalM EstevezM EstolaE et\u00a0al.Model\u2010assisted cohort selection with bias analysis for generating large\u2010scale cohorts from the EHR for oncology research.2020.https:\/\/doi.org\/10.48550\/arXiv.2001.09765"},{"key":"e_1_2_13_9_1","doi-asserted-by":"crossref","unstructured":"MaX LongL MoonS AdamsonBJS BaxiSS.Comparison of population characteristics in real\u2010world clinical oncology databases in the US: Flatiron Health SEER and NPCR.2020. Available from:https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.16.20037143v2","DOI":"10.1101\/2020.03.16.20037143"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4137"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00665-x"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.10.002"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124301"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-145097"},{"key":"e_1_2_13_19_1","unstructured":"ClinicalTrials.gov.A phase 3 study comparing daratumumab VELCADE (bortezomib) lenalidomide and dexamethasone (D\u2010VRd) vs VELCADE lenalidomide and dexamethasone (VRd) in subjects with previously untreated multiple myeloma who are eligible for high\u2010dose therapy. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03710603. Accessed 24 May 2022."},{"key":"e_1_2_13_20_1","unstructured":"ClinicalTrials.gov.A phase 3 randomized open\u2010label multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade\u00ae) lenalidomide and dexamethasone versus bortezomib lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03319667. Accessed 24 May 2022."},{"key":"e_1_2_13_21_1","unstructured":"ClinicalTrials.gov.Effective quadruplet utilization after treatment evaluation (EQUATE): a randomized phase 3 trial for newly diagnosed multiple myeloma not intended for early autologous transplantation. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04566328. Accessed 24 May 2022."},{"key":"e_1_2_13_22_1","unstructured":"ClinicalTrials.gov.A phase 3 study comparing daratumumab VELCADE (bortezomib) lenalidomide and dexamethasone (D\u2010vRd) with VELCADE lenalidomide and dexamethasone (VRd) in subjects with untreated multiple myeloma and for whom hematopoietic stem cell transplant is not planned as initial therapy. Accessed 24 May 2022. Available from:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03652064"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23753"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30099-5"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00389-7"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.04.020"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.0551"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.03.002"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134538"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy073"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137575"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01308-8"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09980-9"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3444"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-609461"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00633-5"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000406"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.739","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T18:51:14Z","timestamp":1700679074000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1002\/jha2.739"],"URL":"https:\/\/doi.org\/10.1002\/jha2.739","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"2023-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}